Unknown

Dataset Information

0

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.


ABSTRACT: Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitumor immunity elicited by anti-PD1. Here, we observed antitumor activity following combinatorial therapy with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor models. Dinaciclib induced a type I IFN gene signature within the tumor, leading us to hypothesize that dinaciclib potentiates the effects of anti-PD1 by eliciting ICD. Indeed, tumor cells treated with dinaciclib showed the hallmarks of ICD including surface calreticulin expression and release of high mobility group box 1 (HMGB1) and ATP. Mice treated with both anti-PD1 and dinaciclib showed increased T cell infiltration and DC activation within the tumor, indicating that this combination improves the overall quality of the immune response generated. These findings identify a potential mechanism for the observed benefit of combining dinaciclib and anti-PD1, in which dinaciclib induces ICD, thereby converting the tumor cell into an endogenous vaccine and boosting the effects of anti-PD1.

SUBMITTER: Hossain DMS 

PROVIDER: S-EPMC5785250 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression.

Hossain Dewan Md Sakib DMS   Javaid Sarah S   Cai Mingmei M   Zhang Chunsheng C   Sawant Anandi A   Hinton Marlene M   Sathe Manjiri M   Grein Jeff J   Blumenschein Wendy W   Pinheiro Elaine M EM   Chackerian Alissa A  

The Journal of clinical investigation 20180116 2


Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitu  ...[more]

Similar Datasets

| S-EPMC6980372 | biostudies-literature
| S-EPMC7946638 | biostudies-literature
| S-EPMC8436107 | biostudies-literature
| S-EPMC7486645 | biostudies-literature
| S-EPMC7733505 | biostudies-literature
| S-EPMC8010109 | biostudies-literature
| S-EPMC9564202 | biostudies-literature
| S-SCDT-EMM-2019-10979 | biostudies-other
| S-EPMC7185221 | biostudies-literature
| S-EPMC7278545 | biostudies-literature